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Abstract 
Background With the introduction of human
papillomavirus (HPV) testing and vaccination in the UK,
health professionals will start to receive questions about
the virus from their patients. This study aimed to identify
the key questions about HPV that British women will ask
when considering having an HPV test or vaccination.
Methods Face-to-face interviews were carried out with 21
women to discover what they wanted to know about HPV.
A thematic framework approach was used to analyse the
data and identify key themes in women’s HPV knowledge
requirements.
Results Women’s questions about HPV fell into six areas:
identity (e.g. What are the symptoms?), cause (e.g. How
do you get HPV?), timeline (e.g. How long does it last?),
consequences (e.g. Does it always cause cervical
cancer?) and control-cure (e.g. Can you prevent
infection?). In addition, they asked procedural questions
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Background
Advances in medical science have demonstrated that
infection with human papillomavirus (HPV) is the key factor
in the aetiology of cervical cancer and genital warts.1
Technologies to test for the presence of the virus are now
available and are being evaluated at selected sites in the
UK.2,3 A prophylactic vaccine has also been developed4 and
this will be offered to all girls aged 12–13 years in the UK
from 2008.5 Progress in this field has been so rapid that
diffusion of HPV information to the public has not kept pace
with scientific advances. Most people have never heard of
HPV and are unaware that cervical cancer has an infectious
aetiology.6,7 However, with testing and vaccination
becoming available, health professionals will start to get
questions about the virus from patients. An understanding of
what questions women may ask could help prepare health
professionals for what they will have to explain. There is
also an urgent need for public education materials (such as
websites and leaflets) that women can be referred to for
answers to their questions, helping them to make informed
decisions about participation in testing and vaccination.
Understanding what women want to know about HPV could
help inform the content and structure of these materials.
Several studies in the USA and Australia have begun to
identify the issues in HPV that women ask about. In 2003,
staff from the American Social Health Association
identified the most frequently asked questions about HPV8
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about testing and vaccination (e.g. Where do I get an HPV
test?). These mapped well onto the dimensions identified
in Leventhal’s description of lay models of illness, called
the ‘Common Sense Model’ (CSM).
Discussion and conclusions These results indicated
that the majority of the questions women asked about
HPV fitted well into the CSM, which therefore provides a
structure for women’s information needs. The findings
could help health professionals understand what
questions they may be expected to answer. Framing
educational materials using the CSM themes may also
help health educators achieve a good fit with what the
public want to know.
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and more recently several qualitative studies have
identified key issues about HPV that both women and men
want to know.9–11 There has been one study in the UK
considering HPV-related information needs in a sample of
women who had recently been screened. Women were
recruited through cervical screening centres in England to
take part in focus groups. After reading information about
HPV, women discussed their responses and identified
various unanswered questions.12 There has been a high
level of consistency between the findings of these studies
despite the different contexts that participants were
recruited from. The most important issues about HPV seem
to relate to transmission, prevalence, consequences,
prevention and treatment.
HPV information should also be scientifically accurate
and minimise any possible stigma that might be associated
with the infection because of its sexually transmitted nature.
Tristram13 used her clinical judgment to identify ten
important points that addressed these criteria. These
included the high prevalence of HPV, spontaneous
clearance, that HPV may be present for some years before
abnormalities arise, and that different HPV types cause
cervical cancer and genital warts. Cuschieri et al.14
reviewed the existing literature on what the population want
to know and what they should know with regard to HPV.
They too focused on the importance of de-stigmatising HPV
and highlighted the importance of emphasising its high
prevalence and predominantly benign nature. They also
noted the need to tell women that condoms are not always
protective and that genital warts and cervical cancer are
distinct consequences of HPV infection.
Key message points
 What women want to know about human papillomavirus
(HPV) can be structured in a theoretical way.
 Women’s questions about HPV relate to six dimensions:
identity (e.g. symptoms), cause, timeline, consequences,
cure-control and procedural aspects (in relation to
vaccination/testing).
 This framework could inform development of
information materials about HPV.
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One aim of this study was to identify the questions that
British women have about HPV. We also examined whether
a theoretical structure widely used in the literature on lay
models of illness would successfully frame the questions
women ask about HPV. This has not been done in previous
studies of HPV information needs. Leventhal’s ‘Common
Sense Model’ (CSM) of illness representations15 has been
successfully applied to a wide variety of illnesses.16–18 The
theory posits that lay cognitive representations of illness fall
into five dimensions: identity (labels/symptoms of the
illness), perceived cause (determinants), controllability
(prevention and treatment), consequences (to health and
quality of life) and timeline (duration). The CSM’s primary
application has been in relation to chronic diseases, but if
the model represents a ‘natural’ cognitive structure of illness
then the questions that women ask about a new infection
such as HPV should map onto the CSM dimensions. If so,
the CSM could also provide a useful framework around
which to structure HPV information for the public.
Methods
Participants
Face-to-face, individual interviews were conducted with a
sample of 21 women aged between 18 and 53 years. A
convenience sample was recruited using a ‘snowballing’
technique. Interviews were carried out at University
College London and women were reimbursed £20 for their
time. The study was conducted in line with the University
Research Ethics Committee guidelines, but we did not seek
independent approval from the ethics board because the
methods used fell within the exemption criteria.
Procedure
Women were asked to describe their background, giving
details of their age, education, employment status, marital
status and cervical screening history. They were then asked
what they knew about cervical cancer and HPV. Because
very few women had even heard of HPV, some basic facts
were presented to women on a card at the start of the
interview (Box 1). These facts were also read aloud by the
interviewer. Women were then asked what additional
information they would need to be sufficiently informed to
make a decision about HPV testing or vaccination. Their
questions were answered as the interview progressed and
the interview ended when they were satisfied with the
information they had received. Two of the authors (LM and
JoW) each carried out one interview and the rest were
conducted by the third author (NG). All interviewers were
female.
Analysis 
Interviews were recorded and transcribed verbatim. We
used a thematic framework analysis, which allowed us to
organise the data in a systematic and manageable way.16
After familiarisation with the transcripts, a framework was
created based on the core themes that emerged from the
interviews. Each question was entered into the thematic
framework under one of these themes. This allowed for
identification of specific questions within each theme.
Results
Characteristics of the study group are shown in Table 1. All
participants were white except one Asian-British woman.
Women’s knowledge of the causes of cervical cancer
varied. Being sexually active was identified as a risk factor,
as was a virus, with HPV also being explicitly mentioned
by two participants. Many women, especially in the
youngest age group, could not suggest any possible cause
for cervical cancer.
Participants were very interested in HPV, but the
number of direct questions ranged from just five to 28
questions. Between them the 21 women generated 300
questions about HPV. Many of their questions were similar,
and all questions could be classified under six themes. The
first five themes were consistent with the illness
representation component of Leventhal’s CSM.15 The
themes have been labelled using terminology from this
model as follows: identity (asymptomatic nature of HPV
and its prevalence), cause (main cause and additional risk
factors), timeline, consequences (cervical cancer, genital
warts, social consequences) and cure-control (possible
prevention, cervical screening, HPV testing, HPV
vaccination). Women also had additional questions about
the procedures for HPV testing and future options for
vaccination, and these are presented as an additional theme.
[NB. In the sections that follow, example questions are
listed for each theme and the participant asking the
question is indicated by a number.]
Identity
Most women wanted to know if there were any signs or
symptoms relating to HPV. They asked about the
prevalence of HPV, and once told that it is very common,
they wanted to know why so many women become
infected.
Does HPV have any symptoms? (P3)
Is it really common in England? (P19)
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Box 1: Information given to women involved in the study
 A virus called human papillomavirus (HPV) is now known to
be involved in the development of cervical cancer (cancer of
the cervix, or neck of the womb).
 For most women, the immune system clears the virus and
there are no health problems associated with it.
 If infection persists it can lead to abnormalities in the cells of
the cervix.
 Regular attendance for smear tests can help to detect the
cell changes that are caused by HPV. These can then be
treated very effectively.
 HPV testing is currently being piloted by the NHS to see if its
use will benefit the current cervical screening programme.
 HPV vaccinations have also been developed and are
currently in the final stage of trials.
Table 1 Characteristics of the study group (n = 21)
Characteristic n
Age (years)
18–25 9
26–33 4
34–41 5
42–49 2
50+ 1
Education status
Degree level 16
A levels 5
Employment status
Employed (full-time) 6
Employed (part-time) 4
Homemaker (full-time) 3
Student 8
Marital status
Married/cohabiting 9
Single 10
Divorced/separated 2
Cervical screening history
Never screened 4
Yes, once 3
Yes, more than once 14
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Cause
All women wanted to know the cause of HPV, and once
told it was sexually transmitted, they asked if this was the
only way to contract it. They asked many questions relating
to additional risk factors (e.g. if HPV was more likely in a
particular age group and whether having more sexual
partners was associated with higher risk). Women asked if
lifestyle factors such as diet or drinking alcohol increased
risk of infection.
How do you contract HPV? (P2)
Can you catch HPV any other way? (P5)
Is HPV more common in younger people? (P5)
Are more promiscuous women at greater risk? (P3)
Does drinking increase your risk? (P10)
Timeline
Women were particularly interested in the time between
contracting HPV and developing cervical cancer. Questions
were raised about the potential for the virus to clear
spontaneously and how long this process took.
How long does it take for HPV to become cervical
cancer? (P3)
So can it clear by itself then? (P13)
For how long can the virus lie dormant? (P13)
Consequences
In relation to cervical cancer, women wanted to know how
common it was for this to be the consequence of HPV, and
whether cervical cancer could be caused by other things.
They also wanted to know if HPV could cause any other
cancers, if it had any effect on pregnancy, and if the virus
had any other effects on the body. The possibility of cancer
being related to genital warts was also raised.
How many cases of HPV become cervical cancer? (P4)
Is HPV the only cause of cervical cancer? (P5)
What other cancers are caused by a virus? (P3)
What about getting pregnant? (P15)
Does HPV have any other effects on your body? (P15)
Are genital warts and cancer related? (P14)
Younger women (i.e. those aged 18–25 years) asked
many questions about the prevalence of cervical cancer and
treatments available for the disease.
How many women get cervical cancer? (P1)
How is cervical cancer treated once you have it? (P5)
Consequences for men were frequently mentioned,
including whether men are just carriers of the virus or are
likely to experience harmful effects. The matter of
disclosing an HPV diagnosis to a sexual partner was raised,
which introduced the issue of indirect social and
psychological consequences from the disclosure.
Can a man get HPV? (P20)
Does it have any effect on men? (P4)
If you test positive should you tell your partner? (P10)
Cure-control
Women asked how they could protect themselves and
whether condoms were an effective way to reduce their
risk. They also wanted to know if there was any treatment
available for HPV, and requested more details about what
was involved in the treatment of pre-cancerous cells. When
it was explained that in most cases HPV clears
spontaneously, women wanted to know how quickly this
could happen and why it did not clear in all cases.
Is there any way to protect yourself against HPV? (P19)
Does using a condom protect you? (P1)
What kind of treatment is there for HPV? (P12)
What does treatment for cell changes involve? (P8)
How quickly does it get cleared? (P8)
Why do some people clear it with their immune system
but others don’t? (P9)
The younger women (i.e. those aged 18–25 years) –
who had no experience of cervical screening because
screening in England begins at the age of 25 years – asked
many questions about cervical screening, including the
purpose of screening, the recommended frequency, and the
age at which screening should be initiated.
How often do you go for screening? (P19)
What age do you start to go for screening? (P19)
Procedures: HPV testing/vaccination
Although the existence of HPV testing and vaccination
would be included in the cure-control dimension, women in
this sample were asked to imagine they were offered
testing/vaccination, and this prompted a variety of
additional procedural questions. Women wanted to know
what the HPV test would involve, and the practicalities of
the test including where it would be carried out, how long
it would take to get results, and if it was included in
screening for sexually transmitted infections (STIs).
Several women also asked how an HPV test would be
different from the current cervical screening procedures.
What does the [HPV] test involve? (P1)
Can you get it at the doctors? (P7)
How long would it take to find out the result? (P7)
Is HPV included in STI testing? (P21)
How would an HPV test differ from a smear test? (P20)
Women were extremely interested in the prospect of
HPV vaccination and asked many questions about
effectiveness, possible risks, mechanisms, research trials,
likely coverage, and availability. They wanted to know how
likely the vaccine was to provide full protection and if it
would reduce deaths from cervical cancer to zero. They
were concerned about adverse effects following the
vaccination including possible side effects in the future.
Women asked if the vaccine would be ‘a bit of the virus’
and if it was possible to get infected with the virus from the
vaccine. They also asked if the vaccine would be only
preventive or also therapeutic, and wondered whether it
would be effective if the virus was ‘dormant’. The
practicalities of vaccination (e.g. How many doses,
whether a booster was required?) also attracted interest.
How effective is the vaccine? (P2)
What are the side effects of the vaccine? (P3)
What are the long-term effects of the vaccine? (P15)
How does the vaccine work, is it a bit of the virus? (P4)
Can you get the virus from the vaccine? (P18)
Is the vaccine for prevention or cure? (P17)
How many times would you have to have the
vaccination? (P6)
Women had many questions about current vaccine
trials, wanting to know details such as how long the trials
had been underway, how the vaccine had been tested, and
who it had been tested on. There was also interest in who
had carried out the trials. Women wanted to know what
exactly the vaccination would protect against, including if
it would protect against all HPV types, genital warts and
any other STIs. They asked questions about who the
vaccine would be offered to, whether the vaccine would be
just for girls, and if it would be targeted at a specific age
group. They wanted to know when the vaccine would be
available and how it would be offered [i.e. through general
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In addition to general questions about HPV, women
asked many specific procedural questions about HPV
testing and vaccination. The younger women also asked
questions about cervical cancer and screening, because at
this age these details were also novel (women are not
invited for cervical screening in England until they attain
the age of 25 years). Context is likely to be very
important in relation to what women want to know.
Women who are thinking about vaccination for their
daughter may focus on very different aspects compared
with women who have received an abnormal smear
result, or women who are simply interested in finding out
more about HPV.
Study limitations
There are several limitations to this study. The analyses
were based on interviews with predominantly white, well-
educated women, and we can not be sure that the same
questions would arise in interviews with women from
different backgrounds; however, we did achieve
saturation in understanding the perceived information
requirements of this group and the similarities between
our results and those of Goldsmith et al.12 suggest the
most important themes in questions about HPV are
consistent across different samples of British women. It
will be essential that public information about HPV is
evaluated with women from a broader demographic
sample to ensure that its content is appropriate for all
women.
Women were encouraged to generate as many questions
as they could in the framework of an interview, and they
may have generated more questions than they would have
asked in a more natural setting. We were particularly
interested in questions about HPV in the context of
vaccination or testing. As neither of these procedures are
routinely available at present, we used a hypothetical
methodology, asking women to ‘imagine you had been
invited for a test or vaccine’, which is an imperfect
substitute for testing reactions to an actual
screening/vaccination invitation.
We also asked women to consider vaccination for
themselves, despite the fact that women of this age are
unlikely to be offered HPV vaccination. It may have been
more pertinent to ask mothers about vaccination for their
daughters or to ask adolescent girls (who will be offered
that vaccination) what questions they have. Future work
could explore whether the same questions would arise in
these groups.
Conclusions
To date, no theoretical framework has been used to
structure the questions women ask about HPV. In this
qualitative study the questions women asked about HPV –
an infection about which they previously knew very little –
mapped well onto the framework of the illness
representations approach (CSM), supplemented with
procedural questions about vaccination and testing. This
could provide a useful framework for information health
professionals ought to be aware of in relation to patients’
information needs. Framing information in this way could
also provide an effective structure to help health educators
present the scientific facts in a way that fits with what the
public want to know.
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practitioners (GPs) or in schools]. They asked if it would be
offered at the same time as other vaccinations and if it
would be possible to opt out of having the vaccine. The
potential cost of the vaccination was also brought up, with
women asking if it was likely to be offered on the National
Health Service (NHS). Women were also interested in the
implications for the screening programme, and particularly
whether vaccination would mean the end of cervical
screening.
How long have they been working on the vaccine? (P5)
Who has the vaccine been tested on? (P15)
Who has been trialling the vaccinations? (P8)
Will the vaccine be for everyone? (P19)
Will vaccination only be for a certain age group? (P10)
When will the vaccine be available? (P4)
Would this be available from the GP? (P13)
Will it be free for everyone? (P19)
Would the vaccine protect against warts too? (P2)
Would I still have to go for smear tests? (P3)
Discussion
The aims of this study were (1) to explore HPV information
needs in a sample of British women both in general and in
the context (albeit hypothetical) of informed consent for
HPV testing or vaccination and (2) to examine the
applicability of a theoretical structure for lay
representations of illness in this context.
The most frequently asked questions regarding HPV
itself in this sample related to symptoms and prevalence,
transmission of the virus, duration of infection, time course
of cancer risk and viral infection, health and social
consequences (e.g. effects on relationships) and prevention
and treatment for HPV. The questions that our sample of
women asked were very similar to those that have been
reported in other qualitative studies in the USA and
Australia8–11 and in one other study of British women who
had recently been for cervical screening.12 They also
mapped reasonably well onto the key points that expert
health professionals suggest should be covered in
educational materials.13,14
We found that the themes that emerged in the
interviews were consistent with a well-known
psychological model of lay representations of illness,
namely Leventhal et al.’s CSM.15 This model identifies
five core dimensions (identity, perceived cause,
controllability, consequences and timeline) that are
activated and modified on the basis of experience of, or
information about, an illness.17 The results of the present
study showed that when people are thinking about a disease
(or in this case an infection) they have not personally
experienced, they seek information on the same five
domains, together with additional practical information.
One feature of the CSM is recognition that the content of
illness representations are not necessarily consistent with
medical facts.18 By structuring scientifically accurate
information in line with the dimensions that lay people use
to conceptualise illnesses, it may be possible to create
greater consistency between the individualised illness
representation and the accepted medical model. This could
be of particular benefit if future experience with the illness
does arise. Although cervical cancer is a possible (albeit
rare) consequence of HPV, the virus itself is not an
identifiable disease and is therefore very different to what
the CSM traditionally refers to; however, we have made the
assumption that the lay public are likely to find this
distinction arbitrary and will find the illness representations
approach useful in this context despite the complexities of
HPV as a causative agent rather than a disease.
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